Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Arcus

This Growth Stock With 137% Upside Faces New Challenge: Buy, Hold or Sell?

Not a collapse, just a pivot toward what matters most. Arcus Biosciences still has plenty of potential.

The Insider Report: Prepare for the Next Dip Buying Opportunity

The Insider Report: Prepare for the Next Dip Buying Opportunity

The turbulence in stocks continued with the Nasdaq reeling from the tech wreck. It finished down 2.74%, while the Dow Jones Industrial Average and the SP 500 finished down 1.91% and 1.94%, respectively. The rotation into healthcare continues to accelerate, and it's really the only sector offering abundant and attractive…

Gilead Sciences/Arcus Biosciences' Investigational Cancer Drug Shows Overall Survival Of Around 27 Months

Gilead Sciences/Arcus Biosciences' Investigational Cancer Drug Shows Overall Survival Of Around 27 Months

On Sunday, Arcus Biosciences Inc. (NYSE:RCUS) announced the first overall survival results from Arm A1 of the Phase 2 EDGE-Gastric study in patients with locally advanced, unresectable, or metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma.

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Jim Cramer Recommends This Energy Stock, But Don't 'Bank It All' On Arcus

On CNBC's “Mad Money Lightning Round,” Jim Cramer recommended buying Uranium Energy Corp. (NYSE:UEC), saying, “I like nuclear.”

Gilead Sciences Lifts Annual Outlook As Yeztugo Launch Nears

Gilead Sciences (NASDAQ:GILD) announced its second-quarter 2025 earnings and revised annual outlook after the market closed on Thursday.

Tyneside animation firm Arcus Studios set for growth with £150,000 investment

The Newcastle company works with the likes of BBC, E4 and the McMillan Trust and is set to create jobs

Birmingham Post

Arcus Posts Encouraging Data For Domvanalimab-Based Regimes In Lung Cancer Settings

Arcus Biosciences Inc (NYSE:RCUS) announced results from the third interim analysis of the ongoing Phase 2 ARC-7 study of zimberelimab vs. domvanalimab plus zimberelimab (doublet) vs. domvanalimab plus zimberelimab and etrumadenant (triplet) as a first-line treatment for metastatic non-small cell lung cancer. In this interim analysis, both domvanalimab-containing arms continued to show meaningful…

inkl

Read news from The Economist, FT, and more,
with one subscription

1

People

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

Gilead Sciences Inc

Gilead Sciences

North of Tyne Combined Authority

Uranium Energy Corp

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Dow Jones Industrial Average

Places

381,019 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play